Literature DB >> 6294785

Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

R N Jones, A L Barry, C Thornsberry.   

Abstract

The level of antimicrobial activity of 3-desacetylcefotaxime was found to be approximately eightfold lower than that of cefotaxime. Variation in the inhibitory effects of desacetylcefotaxime was species dependent. Desacetylcefotaxime was 1-2 log2 dilutions more active than cefotaxime against Pseudomonas acidovorans and Pseudomonas cepacia. Desacetylcefotaxime and cefotaxime were bactericidal, and their minimal inhibitory concentrations were influenced only slightly by increases in the inoculum concentration. Synergy (complete and partial) of 75.8% was noted with the combination. Only with strains of Morganella morganii was the combination antagonistic, but these results were not clinically significant; i.e., all strains remained susceptible to cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6294785     DOI: 10.1093/clinids/4.supplement_2.s366

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  26 in total

1.  In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Third generation cephalosporins in the parenteral to oral switch.

Authors:  D Rimmer
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

4.  Penetration of cefotaxime into respiratory secretions.

Authors:  R B Fick; M R Alexander; R A Prince; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

5.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

6.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins.

Authors:  R N Jones; H W Wilson
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

8.  Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

Authors:  Elsa Maksoud; Berengere Koehl; Aude Facchin; Phuong Ha; Wei Zhao; Florentia Kaguelidou; Malika Benkerrou; Patricia Mariani; Albert Faye; Mathie Lorrot; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.

Authors:  C M Paap; M C Nahata; M A Mentser; J D Mahan; S K Puri; J W Hubbard
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.